1. Scrip
  2. >>Business

Mineralys Looks To Path Ahead For MLS-101 In Hypertension

 
• By Alaric DeArment

The company plans to meet with the FDA before the end of the year to discuss the way forward, including a pivotal study it hopes to launch in 2023 in uncontrolled and resistant hypertension.

Mineralys announced positive topline data from its Phase II study of MLS-101 in hypertension • Source: Shutterstock

With positive topline Phase II data for its aldosterone synthase inhibitor, MLS-101, Mineralys Therapeutics, Inc. is preparing to move forward into the increasingly competitive field of treating patients with hypertension whose condition is uncontrolled or resistant to medication, estimated to affect more than 30 million patients in the US alone.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

Biotech Leaders Fear FDA Disruption Is Causing Delays

 
• By Jessica Merrill

A letter to US Senate HELP Committee Chair Bill Cassiday sounds an alarm about irreparable damage to the FDA, signed by more than 200 biotech executives and investors.

Ferring’s Faith In Bladder Cancer Gene Therapy Starts To Pay Off

 
• By Kevin Grogan

Adstiladrin sales hit €70m in first full year on the market

Q1 VC Financings Fall Short As Early Deals, Mega-Rounds Dip

 
• By Mandy Jackson

Evaluate data show that biopharma companies raising cash in the smallest and largest categories of venture capital financings struggled to meet bars set in prior quarters.